false 0001710340 0001710340 2025-03-18 2025-03-18
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
March 18, 2025
 
Date of Report (Date of earliest event reported)
 
 
 
ETON PHARMACEUTICALS, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-38738
 
37-1858472
(State
 
(Commission
 
(I.R.S. Employer
of incorporation)
 
File Number)
 
Identification Number)
 
 
21925 W. Field Parkway, Suite 235
 
 
Deer Park, Illinois 60010-7208
 
 
(Address of principal executive offices) (Zip code)
 
 
(847) 787-7361
 
 
(Registrants telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbol(s)
 
Name of each exchange on which registered
Common Stock, par value $0.001 per share
 
ETON
 
NASDAQ Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 

 
 
Item 7.01 Regulation FD Disclosure.
 
Attached as Exhibit 99.1 to this Form 8-K are presentation slides that will be used by management of the Company at the Company's Investor Day presentation to be held virtually March 18, 2025.
 
The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01 Financial Statements and Exhibits
 
Exhibit 99.1
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
2

 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: March 18, 2025
By:  
/s/ James R. Gruber                                      
   
James R. Gruber
   
Chief Financial Officer and Secretary
   
(Principal Financial Officer)
 
3

Exhibit 99.1

 

 

 

irday1.jpg
 

irday2.jpg
 

irday3.jpg
 

irday4.jpg
 

irday5.jpg
 

irday6.jpg
 

irday7.jpg
 

irday8.jpg
 

irday9.jpg
 

irday10.jpg
 

irday11.jpg
 

irday12.jpg
 

irday13.jpg
 

irday14.jpg
 

irday15.jpg
 

irday16.jpg
 

irday17.jpg
 

irday18.jpg
 

irday19.jpg
 

irday20.jpg
 

irday21.jpg
 

irday22.jpg
 

irday23.jpg
 

irday24.jpg
 

irday25.jpg
 

irday26.jpg
 

irday27.jpg
 

irday28.jpg
 

irday29.jpg
 

irday30.jpg
 

irday31.jpg
 

irday32.jpg
 

irday33.jpg
 

irday34.jpg
 

irday35.jpg
 

irday36.jpg
 

irday37.jpg
 

irday38.jpg
 

irday39.jpg
 

irday40.jpg
 

irday41.jpg
 

irday42.jpg
 

irday43.jpg
 

irday44.jpg
 

irday45.jpg
 

irday46.jpg
 

irday47.jpg
 

irday48.jpg
 

irday49.jpg
 

irday50.jpg
 

irday51.jpg
 

irday52.jpg
 

irday53.jpg
 

irday54.jpg
 

irday55.jpg
 

irday56.jpg
 

irday57.jpg
 
v3.25.1
Document And Entity Information
Mar. 18, 2025
Document Information [Line Items]  
Entity, Registrant Name ETON PHARMACEUTICALS, INC.
Document, Type 8-K
Document, Period End Date Mar. 18, 2025
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-38738
Entity, Tax Identification Number 37-1858472
Entity, Address, Address Line One 21925 W. Field Parkway, Suite 235
Entity, Address, City or Town Deer Park
Entity, Address, State or Province IL
Entity, Address, Postal Zip Code 60010-7208
City Area Code 847
Local Phone Number 787-7361
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ETON
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001710340

Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Apr 2025 to May 2025 Click Here for more Eton Pharmaceuticals Charts.
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From May 2024 to May 2025 Click Here for more Eton Pharmaceuticals Charts.